3 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow SOM Innovation Biotech SA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety on SOM3355 in Huntington's Disease Chorea Placebo capsules, SOM3355 200 mg capsules, SOM3355 300 mg capsules - Huntington Chorea | Phase 2 | Completed | SOM Innovation Biotech SA | 139 | 2022-08-02 | 2025-08-28 |
| Efficacy and Safety of SOM3355 in Huntington's Disease Chorea SOM3355 100mg BID, SOM3355 200mg BID, Placebo BID - Huntington's Chorea | Phase 2 | Completed | SOM Innovation Biotech SA | 32 | 2018-08-08 | 2019-09-16 |
| Study of SOM0226 in Familial Amyloid Polyneuropathy SOM0226 - Familial Amyloid Polyneuropathy (FAP) | Phase 1 / Phase 2 | Completed | SOM Innovation Biotech SA | 17 | 2014-07-01 | 2016-11-30 |
Chorea (2) · Huntington Disease (2) · Amyloid Neuropathies, Familial (1) · Amyloidosis (1)
BID protein, human (1) · Tolcapone (1) · bevantolol (1)
Spain (3) · France (1) · Germany (1) · Italy (1) · Poland (1) · Switzerland (1) · United Kingdom (1)
PMID 31119947, PMID 36494329, PMID 42857615
2014 (1), 2018 (1)